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Abstract
Despite major research efforts leading to the recent approval of pirfenidone and
nintedanib, the dismal prognosis of idiopathic pulmonary fibrosis (IPF) remains
unchanged. The elaboration of international diagnostic criteria and disease
stratification models based on clinical, physiological, radiological, and
histopathological features has improved the accuracy of IPF diagnosis and
prediction of mortality risk. Nevertheless, given the marked heterogeneity in
clinical phenotype and the considerable overlap of IPF with other fibrotic
interstitial lung diseases (ILDs), about 10% of cases of pulmonary fibrosis
remain unclassifiable. Moreover, currently available tools fail to detect early
IPF, predict the highly variable course of the disease, and assess response to
antifibrotic drugs.
 
Recent advances in understanding the multiple interrelated pathogenic
pathways underlying IPF have identified various molecular phenotypes
resulting from complex interactions among genetic, epigenetic, transcriptional,
post-transcriptional, metabolic, and environmental factors. These different
disease endotypes appear to confer variable susceptibility to the condition,
differing risks of rapid progression, and, possibly, altered responses to therapy.
The development and validation of diagnostic and prognostic biomarkers are
necessary to enable a more precise and earlier diagnosis of IPF and to improve
prediction of future disease behaviour. The availability of approved antifibrotic
therapies together with potential new drugs currently under evaluation also
highlights the need for biomarkers able to predict and assess treatment
responsiveness, thereby allowing individualised treatment based on risk of
progression and drug response. This approach of disease stratification and
personalised medicine is already used in the routine management of many
cancers and provides a potential road map for guiding clinical care in IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is typically introduced as a 
chronic progressive and inevitably fatal scarring lung disease with 
a prognosis worse than that of numerous cancers1,2. Hopefully, 
this is now beginning to change. Although the etiology and the 
pathogenesis of IPF are still incompletely understood, two antifi-
brotic drugs, pirfenidone and nintedanib, have recently been proven 
to be effective in slowing disease progression and are now approved 
as treatments in the United States and Europe3,4.
The recent development of affordable, high-throughput -omics 
technologies has opened the era of systems biology and has ena-
bled the emergence of stratified and personalised medicine. These 
approaches are becoming routine practice in oncology5 and have 
enormous potential in offering new insights into the understanding 
and management of pulmonary diseases6, including IPF.
This article aims to provide an overview of recent developments 
in disentangling the complex interrelated mechanisms involved in 
the pathogenesis of IPF with a particular focus on those that may 
lead to improved diagnosis, stratification of disease behaviour, and 
identification of potential novel therapeutic targets and predictors 
of response to treatment. Considerations concerning the past, 
present, and future pharmacotherapy of IPF were addressed in 
the March 2014 issue of this journal7 and will not be discussed 
in this current review.
Diagnosis
The current approach to IPF diagnosis was first described in 
international guidelines published in 2001, which were recently 
updated. These guidelines define precise diagnostic criteria based 
on clinical, radiological, and histopathological features8 and 
enshrine the place of multidisciplinary discussion among experi-
enced clinicians, radiologists, and pathologists as the gold standard 
method for establishing a diagnosis of IPF. Using the current 
guidelines, in about two-thirds of the cases, a confident diagnosis 
of IPF can be achieved based on an appropriate clinical history in 
association with a typical high-resolution computed tomography 
(HRCT) pattern of usual interstitial pneumonia (UIP) (Figure 1). 
When clinical and HRCT data are non-diagnostic, surgical lung 
biopsy (SLB) is recommended to confirm UIP diagnosis histo-
logically (Figure 2). However, SLB carries considerable risks 
and is often contraindicated in older patients with extensive 
co-morbidities or in those presenting with advanced lung disease9. 
Thus, even in experienced centres, a diagnosis of unclassifiable 
interstitial lung disease (ILD) is assigned to about 10% of patients 
who present with progressive pulmonary fibrosis10.
In a recent study of 117 patients with fibrotic ILDs, bronchoscopic 
lung cryobiopsy has proven to be safe and effective in providing 
adequate lung tissue samples, which enabled increased diagnos-
tic confidence in the multidisciplinary diagnosis of IPF11. This 
minimally invasive technique represents an attractive alternative to 
SLB and may, pending further studies, be included in the diagnostic 
algorithm of IPF and other fibrotic ILDs in the near future.
Figure 1. Typical high-resolution computed tomography (HRCT) 
pattern of usual interstitial pneumonia (UIP). The image shows 
subpleural and basal predominance of reticular opacities associated 
with traction bronchiectasis and honeycomb change (clustered 
cystic airspaces with well-defined thick walls and diameter of 
0.3–1.0 cm).
Figure 2. Photomicrograph of biopsy from a 63-year-old man 
with a multi-disciplinary diagnosis of idiopathic pulmonary 
fibrosis. The patient shows the typical histopathological features of 
usual interstitial pneumonia characterised by spatial heterogeneity 
with areas of subpleural and paraseptal fibrosis and honeycombing 
changes (cystic airspaces lined by bronchiolar epithelium) 
alternating with areas of relatively spared lung parenchyma, 
temporal heterogeneity with admixed areas of active fibrosis with 
fibroblast foci, extracellular matrix deposition (mainly collagen), and 
relative mild or absence of inflammatory cell infiltrate together with 
regions of histologically normal lung tissue.
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Pathogenesis
The heterogeneity in radiological and histopathological appear-
ances, rate of progression, and treatment response observed in 
individuals with IPF suggests that fibrosis arises as a consequence 
of multiple co-activated pathogenic pathways, all of which are 
influenced by complex interactions between endogenous and 
environmental factors12. This multiple-pathway model probably 
explains the disappointing results of therapies targeting single 
receptors or pathways in IPF. Future treatment strategies in IPF 
are likely to focus on combinations of therapies targeting multiple 
pathogenic pathways simultaneously, as is currently used in the 
treatment of many cancers13.
Until 15 years ago, the prevailing pathogenic paradigm in IPF 
was one of chronic inflammation being the precursor to progres-
sive fibrosis. This has shifted over the last decade to a model of 
abnormal wound healing response driven by persistent or recurrent 
alveolar epithelial microinjuries (e.g. cigarette smoke, microaspi-
ration, or infection) in individuals rendered susceptible by ageing 
or genetic predisposition14. Multiple studies have shown that 
alveolar epithelial cell (AEC) apoptosis secondary to injury is fol-
lowed by extravascular coagulation, immune system activation, 
and aberrant persistent activation of AECs, even in the absence of 
the primary stimulus15. These cells, in turn, induce the migration 
and proliferation of local fibroblasts, recruit circulating fibrocytes 
to areas of injury, and promote differentiation of fibroblasts into 
myofibroblasts. This results in the formation of myofibroblast foci, 
the histologic hallmark of UIP, in which persistently activated 
myofibroblasts secrete excessive amounts of extracellular matrix 
(ECM) proteins. Disordered deposition and accumulation of ECM 
components within the interstitium and alveolar spaces lead to 
established fibrosis with progressive destruction of lung architec-
ture and loss of function.
This pathogenic cascade involves complex cell-cell and cell-matrix 
interactions through numerous biochemical mediators, such as 
growth factors, enzymes, chemokines, coagulation factors, and 
reactive oxygen species, all of which have the potential to be influ-
enced by numerous host and environmental factors16–19. Cardinal 
among these is transforming growth factor-beta (TGF-β), a potent 
profibrotic mediator involved in cell recruitment, myofibroblast 
differentiation, and induction of ECM production18–19 (Figure 3).
Disease stratification and personalised medicine
The early manifestations of IPF are, in the absence of a biopsy, 
frequently difficult to distinguish from other ILDs. Furthermore, 
the histological hallmark of IPF, UIP, is found in other disorders 
and so even when a biopsy is available a diagnosis of IPF can 
remain in doubt. A further challenge for clinicians is the fact 
that currently available clinical measures do not allow accurate 
Figure 3. A schematic representing the current model for the pathogenesis of idiopathic pulmonary fibrosis. In genetically susceptible 
individuals, injury activates multiple inflammatory, cell signalling, and repair pathways. Activation of these cascades causes an imbalance 
in profibrotic and antifibrotic mediators. In turn, these mediators activate multiple cell types, causing changes in cellular functioning and 
cell-cell interactions that ultimately result in progressive fibrosis. Abbreviations: CTGF, connective tissue growth factor; FXa, factor Xa; HGF, 
hepatocyte growth factor; IFNγ, interferon-γ; PDGF, platelet-derived growth factor; PGE2, prostaglandin E2; TGFβ, transforming growth 
factor β, Th, T-helper; VEGF, vascular endothelial growth factor.
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prediction of subsequent disease behaviour that can range from 
slowly to rapidly progressive and that, in 5% of cases, is punctuated 
by episodes of rapid acute deterioration or acute exacerbation20.
These challenges highlight the need for the development and 
validation of diagnostic markers specific to IPF and prognostic 
markers of future disease behaviour to guide treatment decisions, 
including referral for transplant21. The recent approval of pir-
fenidone and nintedanib and the identification of new potential 
therapeutic targets have created an urgent need for theragnostic 
markers, i.e. markers able to assess, ideally at an early stage, 
therapeutic response to a given drug. Such markers could be used 
to improve patient selection in clinical trials and also to person-
alise treatment based on an individual’s risk of progression and 
treatment response. This in turn would avoid unnecessarily 
exposing individuals to side effects and would improve the cost- 
effectiveness of treatment. This approach of disease stratification 
and personalised medicine is already used in the routine management of 
cancers and has the potential to improve clinical care in IPF.
Clinical phenotyping
Several clinical, physiologic, radiographic, and pathologic variables 
enable a certain degree of mortality prediction in IPF. Older age, 
male sex, smoking history, low body mass index (BMI), pulmonary 
hypertension, and concomitant emphysema are clinical predictors 
of worse survival20. Longitudinal changes in forced vital capacity 
(FVC) and diffusion capacity for carbon monoxide (DLCO) are more 
predictive of prognosis than baseline values. Thus, a 5–10% decline 
in FVC at 6 months is associated with a more than twofold 
increase in the risk of mortality over the subsequent year22. Using 
relative change in FVC instead of the absolute change enables 
earlier detection of progression with similar prognostic accuracy23. Also 
reported as independent predictors of mortality are baseline 6-minute 
walk distance (6MWD) and change in 6MWD at 6 months24.
Additionally, several multi-dimensional risk prediction models 
integrating various clinical, physiological, and radiological vari-
ables have been validated in IPF25–29 (Table 1). These compos-
ite staging systems are more accurate in predicting baseline and 
longitudinal mortality risk than individual physiological variables 
and permit stratification of IPF patients into groups with distinct 
patterns of survival. Nevertheless, they cannot reliably predict 
future disease behaviour (as measured by rate of decline in FVC) or 
response to treatment30. Additionally, they provide no insights into 
underlying pathobiology and thus fail to identify distinct molecu-
lar phenotypes of disease. The integration of dynamic parameters 
measured over time and biological biomarkers able to reflect 
disease activity is needed to improve the accuracy of disease 
stratification models and guide personalised management31.
Interestingly, the development and greater accessibility of 
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-
PET) may provide a novel method for evaluating disease activ-
ity in IPF. Areas of established honeycomb fibrosis appear to be 
highly metabolically active, as shown by increased 18F-FDG uptake 
on PET/CT32. More importantly, increased 18F-FDG uptake is also 
observed in areas of radiologically normal lung parenchyma on 
HRCT, suggesting that PET/CT may have a higher sensitivity than 
HRCT in detecting early disease in IPF and may thus represent a 
potential useful tool in monitoring disease activity and response to 
treatment33, albeit one which is limited by radiation exposure.
Molecular phenotyping
High-throughput -omics technologies enable the rapid, accurate, 
and simultaneous analysis of high numbers of genes, RNA tran-
scripts, proteins, or metabolites. This in turn has facilitated the 
emergence of systems biology, a multidisciplinary methodology 
based on integration models aimed at understanding biological sys-
tems as a whole, i.e. as a dynamic network of complex interrelated 
networks extending from the genome to the environment. This 
contrasts with linear models that have been used in the past to 
explain the action of individual genes and proteins6. Such multi-
scale modelling should permit mapping of the considerable phe-
notypic heterogeneity of IPF and may enable the identification of 
specific molecular phenotypes associated with clinical outcomes 
that could be used to improve diagnosis accuracy and disease 
stratification21 (Table 2).
Ideal molecular biomarkers should reflect key pathological 
pathways, be easily and accurately measured, have been validated, 
and offer added value to currently used approaches34. IPF stratifica-
tion and personalised management based on molecular biomarkers 
is not yet available in current clinical practice, but recent advances 
in understanding the complex pathobiology of IPF has identi-
fied candidate biomarkers involved in AEC dysfunction, immune 
dysregulation, ECM remodelling, and fibroproliferation35. A pre-
requisite for the use of biomarkers in clinical practice is valida-
tion in large well-phenotyped cohorts with longitudinal follow up 
of both clinical and molecular parameters. Among several cohort 
studies are the COMET (Correlating Outcomes With Biochemical 
Markers to Estimate Time to progression in Idiopathic Pulmonary 
Fibrosis) study in the United States36–38 and the PROFILE (Prospec-
tive Observation of Fibrosis in the Lung Clinical Endpoints) study 
in the United Kingdom39,40. The latter is the largest prospective 
cohort study of incident IPF with over 550 patients recruited, all of 
whom were naïve for antifibrotic therapy at the time of inclusion.
Genetic phenotyping
Two large genome-wide association studies (GWAS) have identi-
fied several common genetic variants associated with susceptibil-
ity to IPF and risk of disease progression. The genes identified are 
involved in host defence, cell-cell adhesion, and DNA repair41,42. 
A single nucleotide polymorphism (SNP) in the promoter region 
of the MUC5B gene, encoding a mucin involved in airway host 
defence43, is significantly associated with sporadic and familial 
IPF44 and, paradoxically, with improved survival45. This MUC5B 
promoter polymorphism is not associated with lung fibrosis in 
scleroderma or sarcoidosis and thus appears to be specific to IPF46. 
Similarly, several SNPs conferring susceptibility to IPF have been 
identified within the TOLLIP locus42. The TOLLIP gene encodes 
for a protein with reduced expression in patients with IPF and that 
regulates part of the innate immune system mediated by Toll-like 
receptor and TGF-β signalling pathways. Surprisingly, the minor 
allele rs5743890 in TOLLIP appears to be protective against the 
development of IPF but when present tends to be associated with 
increased mortality.
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Table 1. Comparison of mortality risk scoring systems in idiopathic pulmonary fibrosis.




DLCO, % pred  
FVC, % pred  
FEV1, % pred  
 
 
Correlation with morphologic 
extent:  
CPI = 91.0 – (0.65 x DLCO) 
– (0.53 x FVC) + (0.34 FEV1) 
More accurate predictor 
of mortality than individual 
functional variables




- : retrospective data; measurement 
variability in DLCO; not yet been replicated
du Bois et al. model26 Age (0–8 pts) 
24-week history of 
respiratory hospitalisation 
(0 or 14 pts) 
FVC, % pred (0–18 pts) 
24-week change in FVC 
(0–21 pts)
1-year mortality risk  
Examples of total score:  
•   0–4 pts: > 2% 
•   22–29 pts: 10–20% 
•   38–40 pts: 40–50% 
•   > 50 pts: > 80%




- : assessed in cohorts with only mild to 
moderate physiological impairment at 





Gender (0–1 pts) 
Age (0–2 pts) 
FVC, % pred (0–2 pts) 
DLCO, % pred (0–3 pts)
Cumulative mortality at 
1, 2, and 3 years  
Examples of 1-year 
mortality risk:  
Stage I (0–3 pts): 6% 
Stage II (4–5 pts): 16% 
Stage III (6–8 pts): 39%




- : retrospective data; possible referral bias 




Gender (0–1 pts) 
Age (0–4 pts) 
FVC, % pred (0–15 pts) 
24-week relative change in 
FVC (0–12 pts) 
DLCO, % pred (0–23 pts) 
Respiratory hospitalisation  
(last 24 weeks) (0 or 14 pts)
1- and 2-year mortality 
risk  
Examples of 1-year 
mortality risk:  
•   0–10 pts: < 2% 
•   27–34 pts: 10–20% 
•   43–45 pts: 40–50% 
•   55–60 pts: ≥ 80%




- : no external validation 
CT-GAP model29 Gender 
Age 
FVC, % pred  
Quantitative CT fibrosis 
score 
Cumulative mortality at 
1, 2, and 3 years  
→ Accuracy comparable 
to that of the original GAP 
model 
Examples of 1-year 
mortality risk:  
Stage I (0–3 pts): 5% 
Stage II (4–5 pts): 19% 
Stage III (6–8 pts): 43%
+ : alternative model when DLCO 




- : retrospective data; requires expertise in 
quantification of CT disease extent
Abbreviations: DLCO, diffusing capacity of carbon monoxide; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; CT, computed 
tomography; % pred, % predicted; pts, points. 
*GAP calculator for more precise estimation of risk available at www.annals.org
Studies based on familial IPF have identified rare genetic variants 
in genes encoding surfactant proteins, including surfactant protein 
C (SFTPC) and A2 (SFTPA2), and in several genes linked to tel-
omere function, such as TERT (which encodes for telomerase reverse 
transcriptase, a component of the telomerase complex responsi-
ble for maintaining telomere length47). Short telomere length as 
well as evidence of lung parenchymal remodelling and epithelial 
dysfunction have been identified in asymptomatic first-degree rela-
tives of familial IPF patients and may represent the earliest stages of 
IPF48. Even in the absence of TERT polymorphisms, short telomeres 
in peripheral blood mononuclear cells (PBMCs) or in AECs are also 
frequently found in IPF patients and portend a poorer prognosis47,49. 
This suggests that both genetic variants and environmental factors 
such as cigarette smoke play a role in telomere shortening.
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Table 2. Candidate molecular biomarkers in idiopathic pulmonary fibrosis.
Biomarkers Potential role Comments Ref.
Genetic MUC5B promoter SNPs Predisposition, 
prognosis
rs35705950 (minor allele): increased susceptibility, 
improved survival;  
rs5743890 (minor allele): reduced susceptibility, 
reduced survival
43–45
Genetic TOLLIP SNPs Predisposition, 
prognosis
42
Genetic SFTPC, SFTPA2 Predisposition 47
Genetic Telomere-related genes 
(TERT, TERC, DKC1, RTEL1) 
Predisposition Short telomeres in leucocytes associated with 
reduced survival
47
Genetic Telomere length Predisposition, 
prognosis
47,49
Transcriptional Lung or peripheral blood 
gene expression profiles 
Diagnosis, prognosis Example: LYCAT mRNA expression in leucocytes 
correlated with lung function and survival
51–56
Epigenetic Lung or peripheral blood 
miRNAs expression profiles 
Diagnosis, prognosis, 
therapeutic targets
Example: Antifibrotic downregulated miRNAs: miR-29, 
Let-7d;  
profibrotic upregulated miRNAs: miR-21, miR-154
64–69
Blood proteins Surfactant proteins (SP-A, 
SP-D)
Diagnosis, prognosis Increased levels predictors of worse survival 71,72
Blood proteins KL-6/MUC1 Diagnosis, prognosis Increased levels predictors of worse survival and 
higher risk of AE
73,82
Blood proteins cCK18 Diagnosis Higher levels in IPF but no association with disease 
severity or outcome
34,35
Blood proteins CCL18 Prognosis Baseline concentration > 150 ng/ml associated with 
higher mortality
74
Blood proteins CXCL13 Prognosis Elevated levels associated with PH, AE, and worse 
survival
75,76
Blood proteins Anti-HSP70 IgG Prognosis IgG positivity associated with functional decline and 
worse survival
34,35
Blood proteins Periostin Prognosis Higher levels in IPF and correlation with disease 
progression
77
Blood proteins Fibulin-1 Diagnosis, prognosis Elevated levels in IPF and correlation with disease 
progression
78
Blood proteins MMP-1, MMP-7 Diagnosis, prognosis Higher levels associated with disease progression and 
worse survival 
79,80
Blood proteins IL-8, ICAM-1 Prognosis High concentrations associated with worse survival 80
Blood proteins LOXL2 Prognosis Higher levels associated with increased risk for 
disease progression
81
Blood proteins ECM- neoepitopes Prognosis Increased concentrations associated with disease 
progression and rate of increase predictor of survival
40
BALF proteins S100A9 protein Diagnosis Significantly higher levels compared to controls and 
other fibrotic ILDs
86
Blood cells Fibrocytes Prognosis Elevated circulating fibrocytes associated with early 
mortality
83
Blood cells Semaphorin 7a+ Tregs Prognosis Increased Sema 7a+ expression on circulating Tregs 




Members of Staphylococcus 
and Streptococcus genera





Total bacterial burden Prognosis Independent predictor of decline in lung function and 
mortality but causal link not established
106
Abbreviations: AE, acute exacerbation; BALF, bronchoalveolar lavage fluid; cCK18, caspase-cleaved cytokeratin-18; CCL18, CC-chemokine ligand 18; 
CXCL13, C-X-C motif chemokine 13; DKC1, dyskeratosis congenital 1 or dyskerin; ECM, extracellular matrix; HSP, heat shock protein; ICAM-1, intercellular 
adhesion molecule-1; IL-8, interleukin-8; ILDs, interstitial lung diseases; KL-6/MUC1, Krebs von den Lungen-6/Mucin 1; LOXL2, lysyl oxidase-like 2; LYCAT, 
lysocardiolipin acyltransferase; miRNAs, microRNAs; MMP, matrix metalloproteinases; MUC5B, mucin 5B; PH, pulmonary hypertension; SFTPA2, surfactant 
protein A2 gene; SFTPC, surfactant protein C gene; RTEL1, regulator of telomere elongation helicase 1; SNPs, single nucleotide polymorphisms; TERC, 
telomerase RNA component; TERT, telomerase reverse transcriptase; TOLLIP, Toll-interactive protein; Tregs, regulatory T cells.
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The biological role of the various genetic variants in the patho-
genesis of IPF has yet to be fully determined. Interestingly, an 
exploratory post hoc study conducted in a subgroup of patients 
participating in a multi-centre randomised control trial of 
N-acetylcysteine treatment for IPF suggests that genetic polymor-
phisms may play a role in determining N-acetylcysteine treatment 
response50. This remains to be confirmed in a prospective clinical 
trial.
Transcriptional phenotyping
Whole RNA microarray analysis of lung tissue from patients 
with different ILDs has identified disease-specific gene expres-
sion signatures that permit UIP to be identified from non-UIP 
samples51,52. Furthermore, the comparison of lung gene expres-
sion profiles of patients with stable or rapidly progressive IPF has 
identified 134 transcripts sufficiently upregulated or downregu-
lated in the progressive IPF group to distinguish stable from pro-
gressive disease53. Similarly, analysis of the peripheral blood 
transcriptome in IPF has identified genes differentially expressed 
between IPF patients and healthy controls and also between those 
with mild and severe disease54,55. For example, mRNA expres-
sion of lysocardiolipin acyltransferase (LYCAT), a cardiolipin- 
remodelling enzyme, in PBMCs of IPF patients appeared to be 
strongly correlated with lung function parameters and survival56.
The identification of these diagnostic or prognostic gene expression 
signatures is a first step towards the development of molecular tests 
that could be applied to bronchoscopy samples or peripheral blood, 
thus allowing less invasive approaches to the diagnosis of IPF and 
earlier identification of individuals at risk of rapid progression.
Epigenetic and microRNA regulation phenotyping
DNA methylation57,58, histone modifications59,60, and noncoding 
microRNAs (miRNAs)61 are epigenetic mechanisms identified as 
contributing to differences in gene expression observed in IPF. 
These regulatory mechanisms are influenced by various factors 
including environmental exposures (cigarette smoke and infection), 
genetic profile, sex, and ageing62. A genome-wide DNA methylation 
analysis of lung tissue identified 2130 significantly differentially 
methylated regions in IPF samples compared to controls, of which 
about a third were associated with significant changes in gene 
expression, including genes identified as IPF-associated common 
genetic variants63. Thus, dysregulated gene expression in the IPF 
lung appears to result from complex interactions between genetic 
and epigenetic factors.
miRNAs influence protein expression by binding to mRNA. Aber-
rant expression of miRNAs has been described in the pathogen-
esis of many cancers. Lung tissue miRNA profiling identified 
significantly increased64 or decreased65 levels of several regulatory 
miRNAs in IPF patients, thereby distinguishing the normal lung 
from the IPF lung and rapidly progressive from slowly progressive 
disease66. TGF-β seems to play a critical role in the upregulation of 
profibrotic miRNAs and downregulation of antifibrotic miRNAs67. 
For example, the direct inhibition of let-7d expression by TGF-β 
in AECs is associated with epithelial to mesenchymal transition 
and collagen deposition68. Similarly, several circulating miRNAs 
appear to be differentially expressed in the serum of IPF patients67. 
Moreover, the expression levels of miR-21, miR-155, and 
miR-101-3p in serum seem to be correlated with FVC and HRCT 
features of IPF69. Interestingly, in mice, intravenous injection of 
synthetic miR-29 during bleomycin-induced pulmonary fibrosis 
restored endogenous miR-29 function and was followed by decreas-
ing collagen expression and reversal of pulmonary fibrosis70. 
These changes in miRNA expression in IPF patients suggest that 
they play an important regulatory role in lung fibrosis and may rep-
resent potential diagnostic and prognostic biomarkers as well as 
therapeutic targets.
Protein and cell biomarkers
A growing number of studies have sought to identify protein- and 
cell-based predictors of IPF disease behaviour. Elevated serum 
levels of several proteins have been associated with worse progno-
sis in IPF, including surfactant protein A (SP-A) and D (SP-D)71,72, 
mucin 1 (KL-6/MUC1)73, CC-chemokine ligand 18 (CCL18)74, 
C-X-C motif chemokine 13 (CXCL13)75,76, periostin77, fibulin-178, 
matrix metalloproteinases MMP-1 and MMP-779,80, interleukin-8 
(IL-8), intercellular adhesion molecule (ICAM)-180, and lysyl 
oxidase-like 2 protein (LOXL2)81. Elevated baseline serum levels 
of KL-6/MUC1 also appear to predict the risk of future acute 
exacerbation82. Similarly, some circulating cells have been associ-
ated with worse survival. Among cellular markers of rapidly pro-
gressive IPF are elevated circulating fibrocytes83 and semaphorin 
7a+ regulatory T cells (Tregs)84.
Serial measurements of serum ECM protein fragments generated 
by MMP activity in 189 IPF patients recruited in the PROFILE 
cohort identified increased serum concentrations of these protein 
fragments in IPF patients compared to controls. More importantly, 
increasing neoepitope concentrations were associated with disease 
progression, and the rate of change over 3 months of 3 of these 
MMP-degraded ECM proteins predicted survival40. These results 
suggest that serial longitudinal measurement of circulating proteins 
have potential for use as prognostic or theragnostic biomarkers.
Studies based on lung tissue or bronchoalveolar lavage fluid 
(BALF) analysis have also identified some candidate diagnostic 
and prognostic biomarkers of IPF, including αvβ6 integrin85, 
S100A9 protein86, and soluble annexin V87.
The value of these protein or cell biomarkers as diagnostic or prog-
nostic factors in IPF needs to be further assessed. Furthermore, inte-
grating validated molecular variables in multivariate risk prediction 
models could improve their accuracy in predicting outcomes in 
IPF. In view of this, Richards and colleagues formulated the per-
sonal clinical and molecular index (PCMI), integrating sex, FVC 
% predicted, DLCO % predicted, and MMP-7 serum concentration, 
which accurately predicted mortality in their validation cohort80. 
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Two other prediction models integrating SP-A and SP-D levels or 
MMP-7, SP-A, and KL-6/MUC1 levels have shown improved pre-
dictability of mortality compared with clinical predictors alone71,88.
Metabolic phenotyping
Metabolomics is the systematic analysis of the complete set of 
metabolites (the metabolome) within a biological system under 
given conditions. This approach offers the potential for a bet-
ter understanding of dysregulated metabolic pathways underly-
ing numerous diseases, including airway diseases such as asthma, 
chronic obstructive pulmonary disease (COPD), and cystic 
fibrosis89. Dysregulated metabolic mechanisms have also been 
highlighted in the pathogenesis of IPF. Increased levels of lactic 
acid in IPF lung tissue compared with controls appear to play a 
role in myofibroblast differentiation via a pH-dependent acti-
vation of TGF-β90. Recently, a metabolomic assay by Xie and 
colleagues demonstrated that augmented aerobic glycolysis, medi-
ated by upregulated glycolytic enzymes, including PFKFB3, 
represented an early and sustained event during myofibroblast 
differentiation91. More importantly, PFKFB3 inhibition mitigated 
myofibroblast differentiation and dampened the profibrotic phe-
notypes of myofibroblasts isolated from IPF lungs. These data 
suggest that glycolytic reprogramming is important in the patho-
genesis of lung fibrosis and therefore represents a potential therapeutic 
target. More research is needed in the field of metabolomics 
to clarify the role of these dysregulated pathways of cellular 
metabolism in the pathogenesis of IPF and to integrate them with 
available genetic, epigenetic, transcriptomic, and proteomic data.
Environmental and host factors
Smoking history has long been described as a prevalent risk factor 
for the development of IPF92, including familial IPF93, and is 
associated with a worse survival94. Some other environmental 
and occupational exposures, including wood, mineral, and metal 
dusts, agriculture, and livestock, have also been associated with 
IPF, although a formal causal link has not been established95. 
Furthermore, air pollution may also play a role in the pathogenesis 
of IPF. A recent study reported a significantly higher risk of acute 
exacerbation of IPF with increased ozone and nitrogen dioxide 
exposure over the preceding 6 weeks96.
Gastroesophageal reflux (GER) is highly prevalent in IPF, 
though often asymptomatic, and confers an increased risk of 
microaspiration97. Anti-acid treatment in IPF has been associated 
in retrospective data with decreased radiologic fibrosis, longer 
survival, and smaller decrease of FVC at 30 weeks98,99. Despite 
growing evidence suggesting that GER and silent microaspiration 
might play a role in the pathogenesis of IPF, there is, to date, no 
confirmation that this association is causative. Consequently, the 
recently updated international guidelines on IPF treatment main-
tained a conditional recommendation for the use of anti-acid 
therapy100. A prospective randomised controlled trial is needed to 
further assess the role of GER and microaspiration in IPF and con-
firm the effectiveness of anti-reflux therapy. 
Infectious processes may play a role in the initiation, progression, 
or exacerbation of IPF. Viral infections, particularly human herpes 
viruses (HHVs), including herpes simplex virus type 1 (HSV-1), 
Epstein-Barr virus (EBV), cytomegalovirus (CMV), HHV-7, and 
HHV-8, have been associated with IPF in several studies101. Whether 
this association is causative has not yet been proven. HHVs have the 
potential to induce endoplasmic reticulum stress and apoptosis102; 
it is therefore hypothesised that viral infection may act as a cofac-
tor in the development of IPF through the reactivation of latent 
HHVs within the alveolar epithelium following exposure to a 
first injury103. Furthermore, a recent study found increased copy 
numbers of EBV and CMV DNA in BALF of IPF patients and, to 
a lesser extent, in first-degree asymptomatic relatives of familial 
IPF patients48. Thus, enhanced HHV replication may trigger epi-
thelial cell stress and participate in disease initiation. A small clini-
cal trial of ganciclovir in individuals with severe IPF with positive 
EBV-IgG serology showed a modest improvement in surrogate 
markers of disease progression104. It has recently been reported that 
influenza infection may also play a role in lung fibrosis by pro-
moting collagen deposition via αvβ6 integrin-mediated TGF-β 
activation in epithelial cells105.
Recent data also suggest a putative role for bacteria and lung 
microbiome in IPF. An analysis of the COMET study showed an 
association between progression of IPF and the presence of 
specific members within the Staphylococcus and Streptococcus 
genera in BALF38. Similarly, Molyneaux and colleagues found an 
increased bacterial load, consisting particularly of Haemophilus, 
Streptococcus, Neisseria, and Veillonella spp., in BALF of IPF 
patients compared to healthy smokers, nonsmokers, and patients 
with moderate COPD106. More importantly, the total bacterial 
burden was an independent predictor of decline in lung function 
and mortality. Whether these differences in lung microbiome are 
a cause or consequence of IPF is unknown. A clinical trial of 
12 months of co-trimoxazole in addition to standard treatment in 
181 patients with fibrotic idiopathic interstitial pneumonia (about 
90% of whom had IPF) showed a reduction in mortality but 
did not slow functional decline107. The exact role of viruses and 
bacteria in the pathogenesis of IPF has yet to be determined and 
the potential for antiviral or antibiotic treatments requires further 
evaluation.
Conclusion
Currently available therapies for IPF are of limited efficacy, and 
the prognosis associated with the condition remains poor. Recent 
advances in our understanding of the complex interrelated mech-
anisms underlying fibrosis in the lung are encouraging and pave 
the way towards an integrated approach to diagnosis, stratifica-
tion, and treatment. It is becoming increasingly clear that genetic 
polymorphisms, whole blood transcriptomic profile, and lavage 
microbiome all predict groups of patients with differing disease 
behaviour and outcomes and potentially variable responses to 
treatment. Furthermore, prospective longitudinal cohort studies 
have started to identify blood biomarkers that have the potential 
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to be used as early measures of treatment response. Considerable 
further research is required to deliver personalised medicine for 
IPF into the clinic, but at least now there is light at the end of 
what has been a very long tunnel.
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